Malaria Vaccine Development Meeting Begins In Washington

Agence France-Presse reports on a malaria vaccine development meeting that kicks off Tuesday in Washington, D.C.

“One of the stars at the meeting will be the RTS,S malaria vaccine, which has been developed by GlaxoSmithKline [GSK] and the PATH Malaria Vaccine Initiative, with funding from” the Bill & Melinda Gates Foundation, the news service writes. The experimental vaccine is currently in “Phase III trials, which test a vaccine’s safety and efficacy on a large scale, in seven African countries – Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. Enrollment is targeted to reach 16,000 children and infants.”

The meeting “follows up a conference on malaria vaccines held three years ago in London,” AFP writes. In a keynote address, Christian Ockenhouse and Thomas Ritchie will discuss U.S. military’s initiatives to fight malaria. GSK researcher Joe Cohen, an inventor of the RTS,S vaccine, will also give a keynote speech.

“People are excited that we may finally have a vaccine that can be registered and in use in five years, and making a huge contribution to what has been an uphill battle for too long,” said Gwynne Oosterbaan, vice president of Global Health Strategies, an international consulting firm. “There’s light at the end of the tunnel,” she said (9/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.